Plain-English translation of NCT06357741 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This clinical trial is testing desuzumab, a medication that works by targeting inflammatory pathways involved in knee osteoarthritis. Rather than just masking pain, this treatment is designed to address the underlying processes that damage cartilage and bone in the knee joint. The study will help researchers understand whether a single injection of this medication can slow or prevent the progression of knee arthritis.
Currently, most treatments for knee osteoarthritis only relieve pain without stopping the disease from getting worse, which eventually leads many patients to need knee replacement surgery. This medication has been successful in treating bone loss in osteoporosis by targeting similar inflammatory pathways, so researchers want to see if it can work the same way for knee arthritis.
You likely qualify if…
You likely don't qualify if…
If enrolled, you will receive a single injection of the medication into your knee area. The study involves 30 participants total, and you will need to commit to follow-up visits so researchers can monitor how your knee responds to the treatment over time. Your participation will help determine whether this new approach can slow knee arthritis progression and potentially help patients avoid surgery in the future.
AI-generated summary from trial data · Jun 15, 2026 · Not medical advice
China
Sponsor
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Enrollment target
~30 participants
Started
August 2021
Primary completion
December 2025
This trial's estimated completion date has passed — the record may not be fully up to date.
Age range
45 Years – 75 Years
Last updated on clinicaltrials.gov in April 2025.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Tian Hongtao, Doctorate
Wuhan Union Medical College Hospital
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.